Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

Y-MABS THERAPEUTICS, INC.

(YMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about Y-MABS THERAPEUTICS, INC.
01/05Y-mAbs Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
AQ
01/03JPMorgan Adjusts Y-mAbs Therapeutics' Price Target to $27 from $30, Keeps Neutral Ratin..
MT
2021Y MABS THERAPEUTICS : Management Change/Compensation - Form 8-K
PU
2021Y-mAbs Therapeutics, Inc. Announces Appointment of Sue Smith as Chief Commercial Office..
CI
2021UPDATE - Y-mAbs Announces Pipeline Update
GL
2021Y MABS THERAPEUTICS : mAbs Announces Pipeline Update - Form 8-K
PU
2021Y-mAbs Announces Pipeline Update
AQ
2021INSIDER SELL : Y-mAbs Therapeutics
MT
2021Y-mAbs Hosting Virtual Research and Development Day
GL
2021Y-mAbs Hosting Virtual Research and Development Day
GL
2021INSIDER SELL : Y-mAbs Therapeutics
MT
2021INSIDER SELL : Y-mAbs Therapeutics
MT
2021Y-mAbs Therapeutics, Inc. Announces Executive Changes
CI
2021Y-mAbs Therapeutics Downgraded, Price Target Cut at JPMorgan
MT
2021JPMorgan Cuts Y-mAbs Therapeutics to Neutral From Overweight, Price Target to $30 From ..
MT
More most relevant news
All news about Y-MABS THERAPEUTICS, INC.
01/05Y-mAbs Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
AQ
01/03JPMorgan Adjusts Y-mAbs Therapeutics' Price Target to $27 from $30, Keeps Neutral Ratin..
MT
2021Y MABS THERAPEUTICS : Management Change/Compensation - Form 8-K
PU
2021Y-mAbs Therapeutics, Inc. Announces Appointment of Sue Smith as Chief Commercial Office..
CI
2021Y-MABS THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statement..
AQ
2021UPDATE - Y-mAbs Announces Pipeline Update
GL
2021Y MABS THERAPEUTICS : mAbs Announces Pipeline Update - Form 8-K
PU
2021Y-MABS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021Y-mAbs Announces Pipeline Update
AQ
2021INSIDER SELL : Y-mAbs Therapeutics
MT
More news
News in other languages on Y-MABS THERAPEUTICS, INC.
2021VENTE D'INITIÉS : Y-mAbs Therapeutics
2021Y-mAbs Therapeutics rétrogradé, objectif de prix réduit chez JPMorgan
2021Earnings Flash (YMAB) Y-MABS THERAPEUTICS affiche un chiffre d'affaires de 9 millions d..
2021Y-mAbs Therapeutics obtient de la FDA la désignation de maladie pédiatrique rare pour l..
2021Danyelza, le produit sous licence de Y-mAbs, bénéficie d'une évaluation prioritaire de ..
2021Earnings Flash (YMAB) Y-MABS THERAPEUTICS affiche un chiffre d'affaires de 11 millions ..
2021SciClone, partenaire de Y-mAbs Therapeutics, cherche à faire approuver le Danyelza pour..
2021Le panel de l'EMA approuve la désignation de produit orphelin pour le candidat médicame..
2021Y-mAbs Therapeutics va commencer à soumettre à nouveau, d'ici la fin de l'année, une de..
2021Y-mAbs Therapeutics présente des données de phase 1 sur Omburtamab
More news
Analyst Recommendations on Y-MABS THERAPEUTICS, INC.
01/03JPMorgan Adjusts Y-mAbs Therapeutics' Price Target to $27 from $30, Keeps Neutral Ratin..
MT
2021JPMorgan Cuts Y-mAbs Therapeutics to Neutral From Overweight, Price Target to $30 From ..
MT
2021Y MABS THERAPEUTICS : HC Wainwright Adjusts Price Target on Y-mAbs Therapeutics to $68 Fro..
MT
2021Y MABS THERAPEUTICS : BofA Securities Upgrades Y-mAbs Therapeutics to Buy From Neutral; Pr..
MT
2021Y MABS THERAPEUTICS : Wedbush Adjusts Price Target on Y-mAbs Therapeutics to $52 From $67 ..
MT
More recommendations
Press releases
01/05Y-mAbs Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
AQ
2021Y MABS THERAPEUTICS : Management Change/Compensation - Form 8-K
PU
2021Y-MABS THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial Statement..
AQ
2021UPDATE - Y-mAbs Announces Pipeline Update
GL
2021Y MABS THERAPEUTICS : mAbs Announces Pipeline Update - Form 8-K
PU
More press releases
Upcoming event on Y-MABS THERAPEUTICS, INC.
03/25/22